Clinical Report: GLP-1 Receptor Agonists Linked to Increased nAMD Risk
Overview
A Canadian study reveals a significant association between GLP-1 receptor agonists and an increased risk of neovascular age-related macular degeneration (nAMD) in older patients with diabetes. The findings underscore the need for clinicians to be aware of potential ocular risks associated with these medications.
Background
The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has surged in diabetes and obesity management. Understanding the ocular risks associated with these medications is crucial, especially given the increasing prevalence of diabetes and its complications. This study highlights a potential link between GLP-1RA use and nAMD, a serious eye condition that can lead to vision loss.
Data Highlights
| Group | Incidence of nAMD |
|---|---|
| GLP-1RA Exposed | 0.2% |
| Unexposed | 0.1% |
Key Findings
- GLP-1RA exposure is associated with a more than twofold increased risk of developing nAMD.
- The study analyzed data from 139,002 patients aged 66 years or older in Ontario, Canada.
- 97.5% of patients in the exposed group were prescribed semaglutide.
- The absolute risk increase for nAMD was approximately 0.1% (0.2% vs 0.1%).
- Further research is needed to explore the mechanisms behind this association.
Clinical Implications
Clinicians should be vigilant in monitoring patients on GLP-1RAs for signs of nAMD, particularly in those with diabetes. Regular ophthalmic evaluations are recommended to assess retinal health and manage potential complications effectively.
Conclusion
The association between GLP-1RA use and increased nAMD risk necessitates further investigation and heightened awareness among healthcare providers. Ongoing monitoring and research are essential to inform clinical guidelines.
References
- Shor R, et al., JAMA Ophthalmology, 2025 -- Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration
- conexiant — GLP-1 Drugs Linked to GI Effects, Uncertain Signals
- Ophthalmology Management — Large US Study Adds to Connection between NAION Risks and GLP1 Drugs
- retinal physician — GLP-1RAs Linked to Reduced Uveitis Risk
- Glaucoma Physician — The Impact of GLP-1 Receptor Agonists on Ocular Disease
- GLP-1 Drugs Linked to GI Effects, Uncertain Signals
- Large US Study Adds to Connection between NAION Risks and GLP1 Drugs
- GLP-1RAs Linked to Reduced Uveitis Risk
- Glucagon-Like Peptide-1 Receptor Agonists and Risk of Neovascular Age-Related Macular Degeneration | JAMA Ophthalmology | JAMA Network
- https://ada.silverchair-cdn.com/ada/content_public/journal/care/issue/49/supplement_1/6/standards-of-care-2026.pdf
- Glucagon-Like Peptide-1 Receptor Agonists and Age-Related Macular Degeneration | Obesity | JAMA Ophthalmology | JAMA Network
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.